最近在心力衰竭治疗方面的成功
Carolyn S P Lam1,2,3, Kieran F Docherty4, Jennifer E Ho5
1Duke-NUS Medical School, Singapore, Singapore. carolyn.lam@duke-nus.edu.sg.
Nature medicine
|October 9, 2023
概括
最近的心力衰竭疗法改善了所有射出分数水平的存活率,并为心肌病提供了新的治疗方法. 然而,护理实施和认识方面的差距仍然是重大挑战.
科学领域:
- 心脏病学 心脏病学
- 心脏衰竭研究研究
- 翻译医学是一种翻译医学.
背景情况:
- 心力衰竭 (HF) 管理已经取得了重大进展,改善了心力衰竭患者的存活率.
- 现在,新型疗法在高频的整个射出分数频谱中显示出改善的结果.
- 特定的心肌病,如心肌粉症和缩性心肌病,通过先进的遗传和分子策略越来越容易控制.
研究的目的:
- 审查最近在心力衰竭治疗方面的突破.
- 为了突出管理特定心肌病的进展.
- 确定心力衰竭护理中的持续挑战和未来方向.
主要方法:
- 审查最近的临床试验和治疗心力衰竭的进展.
- 分析治疗特定心肌病的进展情况.
- 讨论实施科学,疾病意识和心力衰竭中的健康差异.
主要成果:
- 新的疗法已经改善了心力衰竭患者在整个射出小部分的全谱的治疗结果.
- 以前无法治愈的心肌病现在可以得到有效的治疗.
- 在临床试验翻译,护理实施,疾病意识和解决社会经济差异方面仍然存在重大差距.
结论:
- 虽然心力衰竭的治疗已经进步,但仍然存在大量未满足的需求.
- 解决实施差距,提高疾病意识,解决社会经济决定因素对于未来的进步至关重要.
- 持续的研究,精准医学和技术为未来的心力衰竭管理提供了有希望的途径.
相关概念视频
Heart Failure V: Medical Management
10
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
10
Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
441
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
441
Heart Failure IV: Classification and Diagnostic Evaluation
19
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
19
Heart Failure Drugs: Diuretics
400
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
400
Heart Failure Drugs: β-Blockers
346
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
346


